Overview

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal